LONDON, GREATER LONDON, UNITED KINGDOM, January 22, 2025 /EINPresswire / -- What has been the historic growth trend in the abrysvo or arexvy global market and what is expected in the coming years?

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The estimated effectiveness of the respiratory syncytial virus (RSV) among older US veterans in the 2023-2024 respiratory ...

In 2024, companies in the broader market that paid dividends returned around 35% of their net income and 45% of their free ...

We recently compiled a list of the 10 Best High-Yield Dividend Stocks To Invest In. In this article, we are going to take a ...

This week we welcomed the federal government's announcement that a respiratory syncytial virus (RSV) vaccine for pregnant women would be included on ...

Vaccinating pregnant women against RSV reduced the risk of infection in their infants by 61% compared with newborns with ...

GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting up what looks set to be a highly lucrative – and likely ...

GSK and Pfizer’s full-year financial results show that the former is currently winning the battle for take-up of their rival respiratory syncytial virus (RSV) vaccines, although, there are signs ...